HK82392A - Polyoxypropylene-polyoxyethylene block polymer based adjuvants and vaccines using them - Google Patents

Polyoxypropylene-polyoxyethylene block polymer based adjuvants and vaccines using them Download PDF

Info

Publication number
HK82392A
HK82392A HK823/92A HK82392A HK82392A HK 82392 A HK82392 A HK 82392A HK 823/92 A HK823/92 A HK 823/92A HK 82392 A HK82392 A HK 82392A HK 82392 A HK82392 A HK 82392A
Authority
HK
Hong Kong
Prior art keywords
amount
polyoxyethylene
volume
glycopeptide
composition according
Prior art date
Application number
HK823/92A
Other languages
German (de)
English (en)
French (fr)
Inventor
Anthony Clifford Allison
Noelene Elva Byars
Original Assignee
Syntex (U.S.A.) Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex (U.S.A.) Inc. filed Critical Syntex (U.S.A.) Inc.
Publication of HK82392A publication Critical patent/HK82392A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
    • Y10S516/01—Wetting, emulsifying, dispersing, or stabilizing agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
    • Y10S516/01—Wetting, emulsifying, dispersing, or stabilizing agents
    • Y10S516/02—Organic and inorganic agents containing, except water
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polyethers (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
HK823/92A 1983-08-22 1992-10-22 Polyoxypropylene-polyoxyethylene block polymer based adjuvants and vaccines using them HK82392A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/525,190 US4606918A (en) 1983-08-22 1983-08-22 Polyoxypropylene-polyoxyethylene block polymer based adjuvants

Publications (1)

Publication Number Publication Date
HK82392A true HK82392A (en) 1992-10-30

Family

ID=24092296

Family Applications (1)

Application Number Title Priority Date Filing Date
HK823/92A HK82392A (en) 1983-08-22 1992-10-22 Polyoxypropylene-polyoxyethylene block polymer based adjuvants and vaccines using them

Country Status (14)

Country Link
US (1) US4606918A (da)
EP (1) EP0135376B1 (da)
JP (2) JPH0617314B2 (da)
AT (1) ATE58062T1 (da)
AU (1) AU578907B2 (da)
CA (1) CA1236017A (da)
DE (1) DE3483553D1 (da)
DK (1) DK167173B1 (da)
HK (1) HK82392A (da)
IE (1) IE58035B1 (da)
IL (1) IL72740A (da)
NZ (1) NZ209293A (da)
PH (1) PH21112A (da)
ZA (1) ZA846504B (da)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4933179A (en) * 1983-08-22 1990-06-12 Syntex (U.S.A.) Inc. Feline leukemia virus antigen vaccines
US4857318A (en) * 1983-11-07 1989-08-15 Syntex (U.S.A.) Inc. Bordetella bronchiseptica pilus subunit protein vaccine effective against bordetella pertussis
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
JPS6270319A (ja) * 1985-07-30 1987-03-31 インタ−ナシヨナル・ミネラルズ・アンド・ケミカル・コ−ポレイシヨン 成長促進ホルモンの安定化
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US5811088A (en) * 1987-02-20 1998-09-22 Emory University Antiinfective compounds and methods of use
US5565209A (en) * 1987-03-17 1996-10-15 Akzo Nobel N.V. Adjuvant mixture
EP0283085B1 (en) * 1987-03-17 1992-11-11 Akzo N.V. Adjuvant mixture
DE3855807T2 (de) * 1987-11-03 1997-06-12 Syntex (U.S.A.) Inc., Palo Alto, Calif. Einen Tetra-Polyol enthaltendes Impfstoff-Adjuvans
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
ZA888577B (en) * 1987-11-27 1989-08-30 Akzo Nv Stabilization of antibodies
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
NZ238731A (en) * 1990-06-27 1996-02-27 Univ Emory Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide
FI925835A0 (fi) * 1990-06-29 1992-12-22 Chiron Corp Vacciner innehaollande liposomer
FR2672496B3 (fr) * 1990-07-18 1993-05-28 Vacsyn France Sa Compositions a base de substances hydrophobes, solubilisables dans un solvant aqueux, leur procede d'obtention, et leurs utilisations notamment dans le domaine pharmaceutique.
FR2664813B1 (fr) * 1990-07-18 1995-01-13 Vacsyn France Sa Compositions a base de substances hydrophobes, solubilisables dans un solvant aqueux, leur procede d'obtention, et leurs utilisations notamment dans le domaine pharmaceutique.
ATE187154T1 (de) * 1991-03-19 1999-12-15 Cytrx Corp Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität
US20020123476A1 (en) * 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US5696298A (en) * 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US7202225B1 (en) 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
USRE38558E1 (en) 1991-03-19 2004-07-20 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
AU2316892A (en) * 1991-06-27 1993-01-25 Emory University Multiple emulsions and methods of preparation
US5622649A (en) * 1991-06-27 1997-04-22 Emory University Multiple emulsions and methods of preparation
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5342612A (en) * 1991-12-20 1994-08-30 American Cyanamid Company Compositions for the treatment of mammalian diseases
JP3723231B2 (ja) * 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
AU3361093A (en) * 1992-01-20 1993-08-03 Peptech (Uk) Limited Use of muramyl peptides for enhancing animal production
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
PT968722E (pt) * 1994-05-10 2007-09-06 Wyeth Corp Vacina viva melhorada contra brsv.
US6156319A (en) * 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
EP1181937A3 (en) * 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
ATE214603T1 (de) * 1995-06-30 2002-04-15 American Cyanamid Co Stabile makrolide und makrolide imptstoff- zusammensetzungen
EP0781559B1 (en) * 1995-11-30 2007-02-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Oil adjuvant vaccine and method for preparing same
WO1997046204A2 (en) 1996-06-05 1997-12-11 Ashmont Holdings Limited Injectable compositions
JP4598201B2 (ja) * 1997-04-08 2010-12-15 メルク・シャープ・エンド・ドーム・コーポレイション 安定化ヒトパピローマウイルス製剤
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
NZ514323A (en) * 1999-03-24 2003-03-28 Secr Defence A immunostimulant containing an acitive agent and an adjuvant which increases the effect of the active agent
SE9902364D0 (sv) * 1999-06-21 1999-06-21 Astra Ab New process
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
WO2005013918A2 (en) 2003-02-28 2005-02-17 The Trustees Of The University Of Pennsylvania Compositions, methods and kits relating to poxvirus subunit vaccines
KR100720213B1 (ko) * 2003-04-04 2007-05-21 화이자 프로덕츠 인코포레이티드 미세 유동화된 수중 유적형 유화액 및 백신 조성물
CA2571035A1 (en) * 2004-06-25 2006-01-12 Id Biomedical Corporation Of Quebec Compositions and methods for treating neurological disorders
JP2008522951A (ja) * 2004-07-19 2008-07-03 ベイラー・カレツジ・オブ・メデイシン サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
US7868159B2 (en) * 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
BRPI0708842A2 (pt) * 2006-03-28 2011-06-14 Gelesis Inc uso de materiais polimÉricos com outras substÂncias para aumento do desempenho
CN101678082B (zh) 2007-03-26 2013-06-19 再生医药有限公司 使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
JP5334462B2 (ja) 2007-06-11 2013-11-06 花王株式会社 脂肪酸エステルの製造法
US8324369B2 (en) * 2007-11-30 2012-12-04 Baylor College Of Medicine Dendritic cell vaccine compositions and uses of same
WO2009073179A2 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
WO2011038002A1 (en) 2009-09-22 2011-03-31 Yale University Immunogenic epitopes as targets for universal cancer vaccines
CA2797052A1 (en) 2010-04-23 2011-10-27 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphyloccocus vaccine
US8716469B2 (en) 2010-04-27 2014-05-06 Ancora Pharmaceuticals, Inc. Synthetic oligosaccharides for Moraxella vaccine
WO2011149778A1 (en) 2010-05-26 2011-12-01 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for neisseria meningitis vaccine
ES2657705T3 (es) 2010-06-23 2018-03-06 Deutsches Krebsforschungszentrum Secuencias de virus TT específicas y moléculas de ADN quiméricas de células hospedadoras de virus TT para uso en el diagnóstico, prevención y tratamiento del cáncer y la autoinmunidad
US9550811B2 (en) 2010-12-02 2017-01-24 Bionor Immuno As Peptide scaffold design
US9493514B2 (en) 2011-01-06 2016-11-15 Bionor Immuno As Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes
US9446112B2 (en) 2011-07-12 2016-09-20 Philadelphia Health & Education Corporation Clostridium difficile DNA vaccine
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
JP6310909B2 (ja) 2012-06-06 2018-04-11 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド
JP5971652B2 (ja) 2012-10-09 2016-08-17 三菱重工業株式会社 石炭不活性化処理装置
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
EP2868751A1 (en) 2013-10-30 2015-05-06 Deutsches Krebsforschungszentrum HCBI sequences as an early marker for the future development of cancer and diseases of the CNS and as a target for cancer treatment and prevention
EP2966176A1 (en) 2014-07-10 2016-01-13 Deutsches Krebsforschungszentrum HCBI, MSBI, MSSI and CMI sequences as an early marker for the future development of cancer and diseases of the CNS and as a target for the treatment and prevention of these diseases
US20220089670A1 (en) 2018-12-28 2022-03-24 University Of Rochester Gene Therapy for BEST1 Dominant Mutations
EP3686289A1 (en) 2019-01-24 2020-07-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Cmi sequences as an early marker for the future development of cancer, atherosclerosis, diabetes and diseases of the cns and as a target for the treatment and prevention of these diseases
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine
WO2025096754A1 (en) 2023-10-31 2025-05-08 Musc Foundation For Research Development The use of enolase inhibitor pomhex for treatment of fibrosis
WO2026015821A1 (en) 2024-07-12 2026-01-15 University Of Rochester Antibiotic alkaloid and methods of generating and use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2674619A (en) * 1953-10-19 1954-04-06 Wyandotte Chemicals Corp Polyoxyalkylene compounds
US3867521A (en) * 1970-08-26 1975-02-18 Scherer Corp R P Method for absorption of drugs
BE795516A (fr) * 1972-02-17 1973-08-16 Ciba Geigy Preparations de peptides huileuses et injectables et procede pour leur preparation
US3869546A (en) * 1972-12-22 1975-03-04 Cutter Lab Adjuvant compositions and medicinal mixtures comprising them
US4186194A (en) * 1973-10-23 1980-01-29 Agence Nationale De Valorisation De La Recherche (Anvar) Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
IL48325A (en) * 1974-10-22 1979-05-31 Anvar Immunological-free adjuvant compositions containing n-acetyl muramyl-alanyl-d-isoglutamine or n-acetyl-muramyl-l-alanyl-d-glutamicn acid
US4370265A (en) * 1974-10-22 1983-01-25 Agence Nationale De Valorisation Water soluble agents effective as immunological adjuvants for stimulating in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
US4148869A (en) * 1975-03-06 1979-04-10 Baxter Travenol Laboratories, Inc. Immunological reagent and method of using same
FR2313078A1 (fr) * 1975-02-07 1976-12-31 Anvar Composition a base d'huile vegetale metabolisable et d'eau, utilisable notamment pour la constitution de preparations adjuvantes, ces preparations adjuvantes et leur procede d'obtention
US4082736A (en) * 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
US4082735A (en) * 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
GB1563561A (en) * 1976-06-23 1980-03-26 Daiichi Seiyaku Co Muramyldipeptide derivatives and process for the preparation thereof
FR2358159A1 (fr) * 1976-07-16 1978-02-10 Anvar Le diamide de l'acide 2-(2-acetamido-2-deoxy-3 - o-d-glucopyranosyl) - d-propionyl-l-alanyl-d-glutamique et medicaments le contenant
FR2368282A1 (fr) * 1976-10-22 1978-05-19 Anvar Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine
FR2428050A1 (fr) * 1978-06-05 1980-01-04 Anvar Oligomeres de composes du type muramyl-peptide et medicaments les contenant
JPS5543030A (en) * 1978-09-21 1980-03-26 Dai Ichi Seiyaku Co Ltd Prophylactic and remedy for microbial infection disease
FR2449697A1 (fr) * 1979-02-20 1980-09-19 Anvar Nouveaux muramyl-peptides substitues sur un azote peptidique et medicaments les contenant
JPS55111499A (en) * 1979-02-21 1980-08-28 Takeda Chem Ind Ltd Glucosamine derivative and its preparation
CA1185237A (en) * 1979-02-28 1985-04-09 Yuichi Yamamura 6-deoxyglucosamine-peptide derivatives, their production and use
US4384974A (en) * 1979-07-27 1983-05-24 Revlon, Inc. Stable water-in-oil emulsions
FI803077A7 (fi) * 1979-10-12 1981-04-13 Ciba Geigy Ag Foerfarande foer framstaellning av myramylpeptider
US4409209A (en) * 1979-10-12 1983-10-11 Ciba-Geigy Corporation Novel phosphorylmuramyl peptides and processes for the manufacture thereof
US4406889A (en) * 1980-02-15 1983-09-27 Ciba-Geigy Corporation Derivatives of aldohexoses, intermediates, processes for their manufacture, preparations containing such compounds, and their use
GR78246B (da) * 1981-01-23 1984-09-26 Ciba Geigy Ag
US4397870A (en) * 1982-07-27 1983-08-09 The University Of Pennsylvania Process for prolonging retention of emulsion particles in the bloodstream
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants

Also Published As

Publication number Publication date
DK400684D0 (da) 1984-08-21
IE58035B1 (en) 1993-06-16
IL72740A (en) 1988-02-29
IL72740A0 (en) 1984-11-30
EP0135376A3 (en) 1986-12-30
US4606918A (en) 1986-08-19
JPH0617314B2 (ja) 1994-03-09
DE3483553D1 (de) 1990-12-13
DK167173B1 (da) 1993-09-13
JPH0665097A (ja) 1994-03-08
AU578907B2 (en) 1988-11-10
DK400684A (da) 1985-02-23
JP2557603B2 (ja) 1996-11-27
PH21112A (en) 1987-07-16
CA1236017A (en) 1988-05-03
AU3225184A (en) 1985-02-28
JPS60105630A (ja) 1985-06-11
IE842148L (en) 1985-02-22
ATE58062T1 (de) 1990-11-15
ZA846504B (en) 1986-03-26
NZ209293A (en) 1988-10-28
EP0135376A2 (en) 1985-03-27
EP0135376B1 (en) 1990-11-07

Similar Documents

Publication Publication Date Title
EP0135376B1 (en) Polyoxypropylene-polyoxyethylene block polymer based adjuvants and vaccines using them
US4772466A (en) Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4770874A (en) Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5709879A (en) Vaccine compositions containing liposomes
CA2017507C (en) Adjuvant formulation comprising a submicron oil droplet emulsion
US5376369A (en) Vaccine adjuvant
AU654824B2 (en) Vaccine compositions containing liposomes
JP2746272B2 (ja) ワクチンアジュバント
US4933179A (en) Feline leukemia virus antigen vaccines
IE940549L (en) Vaccine adjuvant

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20040820

PE Patent expired